VX-745

DRUG3 trials

Sponsors

EIP Pharma Inc, University Hospital, Toulouse

Conditions

Alzheimer DiseaseAlzheimer's DiseaseMild Cognitive Impairment

Phase 2

A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

CompletedNCT02423122

EIP Pharma IncAlzheimer's Disease, Mild Cognitive Impairment

Start: 2015-04-30End: 2016-09-30Updated: 2019-06-14

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

CompletedNCT02423200

EIP Pharma IncAlzheimer's Disease

Start: 2015-04-30End: 2016-11-30Updated: 2018-04-03

Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients

CompletedNCT03435861

University Hospital, ToulouseAlzheimer Disease

Start: 2018-10-08End: 2021-06-30Updated: 2023-06-22

Related Papers

Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer’s disease

Journal of Neuroinflammation2025-11-24

Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.

2024-01-015 citations